Meta-analysis of the clinical outcome of carbapenem monotherapy in the adjunctive treatment of intra-abdominal infections

American Journal of Surgery

Volumn 174, Issue 3, 1997, Pages 284-290

  Chang, David C ^a   Wilson, Samuel E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM;

ABDOMINAL INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; DRUG EFFICACY; HUMAN; MEDICAL INFORMATION; MEDICAL RECORD; META ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL;

ABDOMEN; BACTERIAL INFECTIONS; CARBAPENEMS; DRUG THERAPY, COMBINATION; HUMANS; IMIPENEM; RANDOMIZED CONTROLLED TRIALS; THIENAMYCINS;

EID: 0030866719     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(97)00137-2     Document Type: Article

References (17)

1. Wiseman LR, Wagstaff AJ, Brogden RN, Bryson HM. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1995;50(1):73-101.
2. Drusano GL, Hutchison M. The pharmacokinetics of meropenem. Scand J Infect Dis. Supplementum. 1995;96(suppl):11-16.
3. Sumita Y, Fukasawa M, Okuda T. Comparison of two carbapenems, SM-7338 and imipenem: affinities for penicillin-binding proteins and morphological changes. J Antibiot Tokyo. 1990;43:314-320.
4. Eklund AE, Nord CE. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group. J Antimicrob Chemother. 1993;31(suppl A):79-85.
5. Brismar B, Malmborg AS, Tunevall G, et al. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections. Antimicrob Agents Chemother. 1992;36(12):2766-2773.
6. Berne TV, Yellin AE, Appleman MD, et al. Meropenem versus tobramycin with clindamycin in the antibiotic management of patients with advanced appendicitis. J Am Coll Surg. 1996; 182(5):403-407.
7. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research. Belmont, California: Lifetime Learning Publications; 1982.
8. Condon RE, Walker AP, Sirinek KR, et al. Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis. 1995;21(3):544-550.
9. Solomkin JS, Reinhart HH, Dellinger EP, et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infect ion Study Group. Ann Surg. 1996;223(3):303-315.
10. Huizinga WK, Warren BL, Baker LW, et al. Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. J Antimicrob Chemother. 1995;36(suppl A):179-189.
11. de Groot HG, Hustinx PA, Lampe AS, Oosterwijk WM. Comparison of imipenem/cilastatin with the combination of aztreonam and clindamycin in the treatment of intra-abdominal infections. J Antimicrob Chemother. 1993;32(3):491-500.
12. Niinikoski J, Havia T, Alhava E, et al. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections. Surg Gynecol Obstet. 1993;176(3):255-261.
13. Eckhauser FE, Knol JA, Raper SE, et al. Efficacy of two comparative antibiotic regimens in the treatment of serious intra-abdominal infections: results of a multicenter study. Clin Therapeut. 1992;14(1):97-109.
14. Solomkin JS, Dellinger EP, Christou NV, Busuttil RW. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/ clindamycin for intra-abdominal infections. Ann Surg. 1990;212(5):581-591.
15. Poenaru D, De Santis M, Christou NV. Imipenem versus tobramycin - antianaerobe antibiotic therapy in intra-abdominal infections. Can J Surg. 1990;33(5):415-422.
16. Gonzenbach HR, Simmen HP, Amgwerd R. Imipenem (N-F-thienamycin) versus netilmicin plus clindamycin. A controlled and randomized comparison in intra-abdominal infections. Ann Surg. 1987;205(3):271-275.
17. Edwards JR, Turner PJ. Laboratory data which differentiate meropenem and imipenem. Scand J Infect Dis. Supplementum, 1995;96(suppl):5-10.